Loading...

Nika BioTechnology, Inc.

NIKAPNK
Healthcare
Drug Manufacturers - Specialty & Generic
$0.95
$0.00(0.00%)

Nika BioTechnology, Inc. (NIKA) Stock Competitors & Peer Comparison

See (NIKA) competitors and their performances in Stock Market.

Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
NIKA$0.95+0.00%972.9MN/AN/AN/A
MKGAF$128.13+1.25%55.7B17.31$7.40+1.96%
MKKGY$25.07-0.56%53.4B16.93$1.48+1.99%
TKPHF$27.50+0.00%43B48.25$0.57+4.87%
IPSEY$32.22+0.00%42.6B20.65$1.56+0.85%
HLNCF$4.66-2.92%41.9B22.19$0.21+1.83%
SDZNY$56.78-0.92%24.3B-2825.00-$0.02+1.18%
ESALY$61.51-2.11%17.6B20.54$3.00N/A
TEVJF$14.00+0.00%16.1B-93.33-$0.15N/A
SGIOY$8.70+0.37%14.8B12.99$0.67+1.84%
Showing 1 to 10 of 100 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

NIKA vs MKGAF Comparison August 2025

NIKA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NIKA stands at 972.9M. In comparison, MKGAF has a market cap of 55.7B. Regarding current trading prices, NIKA is priced at $0.95, while MKGAF trades at $128.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NIKA currently has a P/E ratio of N/A, whereas MKGAF's P/E ratio is 17.31. In terms of profitability, NIKA's ROE is +0.39%, compared to MKGAF's ROE of +0.10%. Regarding short-term risk, NIKA is less volatile compared to MKGAF. This indicates potentially lower risk in terms of short-term price fluctuations for NIKA.Check MKGAF's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions

;